Dados do Trabalho

Título

Use of monoclonal antibodies in patients with migraine: subjective assessment of use and improvement with these drugs Introduction: Migraine is one of the most frequent diseases in neurological clinical practice, with economic and social effects for pat

Resumo

Introduction: Migraine is one of the most frequent diseases in neurological clinical practice, with economic and social effects for patients and the health system. The disease treatment is costly and those who suffer from migraine are affected in multiple domains. The prophylactic treatment uses antidepressants, anticonvulsants, triptans, among other drugs. They are safe drugs but have low efficacy, after all, 35% of patients - treated with Triptains - overgoing randomized clinical trials did not improve, and 40% of them experienced side effects. In an attempt to chance the outcome of the scenario, alternative therapies, such as immunological therapies, with use of Monoclonal Antibodies (mAb) such as Ajovy, Emigality and Pasurta, intend to improve the perspectives for patients and direct the investments of the health system in efficient treatments.

Objective: To carry out a subjective evaluation with patients treated at the Proneuro Clinic, in the city of Cascavel-PR, who used mAb for the treatment of migraine, verifying if there was an improvement in the clinical condition with the new therapy.

Method: This is a subjective assessment with the application of a questionnaire, carried out through calls, clarifying relevant information about the outcomes of immune therapy.

Results: The sample consisted of 68 individuals diagnosed with migraine, treated by the same neurologist, who were instructed to use mAb. 34 did not answer the calls, 14 never underwent the treatment due to the high cost and 20 used mAb and answered the questionnaire. The results show that 70% of the collaborating patients resorted to use the immunological therapy because the previous treatments did not present good efficacy. 30% made the substitution due to side effects such as paresthesia, xerostomia and dizziness. Also, it was found that 70% of patients who used mAb had a reduction in the frequency of migraine attacks and 85% reported relief in intensity. However, 30% pointed out that the frequency remained the same and the intensity in 15% of them also did not change.

Conclusion: The result with the mAb has a statistically significant effect when compared to conventional treatment. However, low adherence, due to the high cost, prevents the therapy from being applied globally so that the disease can have reasonable control in the majority of the population.

Palavras Chave

Migraine, Immunological therapy, mAb.